Pharmacies and Drug Retailers (U.S.) — NAICS 45611

NAICS = North American Industry Classification System, the federal standard for grouping businesses by activity. This page covers the 5-digit industry 45611; the deeper leaf-level page is 456110.

1. Overview

NAICS 45611 is the "Pharmacies and Drug Retailers" industry — the stores and mail-order operations that dispense prescription and over-the-counter (OTC) medicines to the public, from the corner CVS or Walgreens to a single-location independent drugstore to a mail pharmacy that ships a 90-day supply to your door. It is a large, everyday-essential business with defensive demand but famously stressed profits: reimbursement per prescription has been squeezed for a decade by the middlemen who set pharmacy pay (pharmacy benefit managers, or PBMs), and the result has been mass store closures even as prescription volume rises.

This is a rollup page. NAICS 45611 contains exactly one child industry — 456110, which carries the same name — so the two levels are effectively identical in scope, size, and economics. This page gives the industry's own federal ground-truth figures and orients you; for the full treatment (how the money works, the investable universe, regulation, risks, and how to invest), read the leaf primer for 456110.

2. What's inside — and why this level equals its one child

The federal classification places a single detailed industry inside 45611:

Because there is only one child, everything counted in 45611 is also counted in 456110 and vice versa. There is no aggregation of multiple sub-industries happening here — the 5-digit "industry" and the 6-digit "national industry" are the same population of businesses.

Scope, in brief. The code covers establishments "generally known as pharmacies and drug retailers engaged in retailing prescription or nonprescription drugs and medicines" [1] — chain drugstores, independent community pharmacies, stand-alone mail-order and online pharmacies, and the front-of-store merchandise (cosmetics, snacks, health aids) these outlets also sell. It excludes pharmacy benefit managers (NAICS 524292), vitamin/supplement retailers (456191), drug wholesalers (424210), and — importantly — pharmacy counters inside supermarkets, supercenters, and warehouse clubs, which are booked under their store's primary code (e.g., 455211, 445110) [1]. See 456110 for the full inclusion/exclusion list.

3. Size (this level's federal figures)

Our ground-truth statistics for NAICS 45611 come from the 2022 Economic Census concentration file. Because 45611 has one child, these equal the 456110 figures:

The HHI is a standard concentration gauge (10,000 = pure monopoly); 1,710.8 is what regulators treat as moderately-to-highly concentrated. In plain terms: four chains take roughly 71% of the industry's revenue, then a very long tail of small independents makes up the rest [2].

What our ground-truth for this level does not include. Our ingested file for 45611 carries only the concentration statistics above — it does not contain establishment counts, employment, or payroll for this level. Those figures exist at the identical child, 456110, drawn from County Business Patterns 2023 (~41,792 establishments; ~691,152 paid employees; ~$30.7 billion annual payroll) [3]; because the levels are identical, they apply to 45611 as well. The federal Small Business Administration (SBA) small-business size standard for this industry is $37.5 million in average annual receipts [4] — a classification rule, not a market-size estimate.

Undercount caveats. Two gaps understate the true "pharmacy economy." First, the Census counts employer establishments, so the smallest owner-operated (nonemployer) pharmacies are missed — a modest omission here, since this is not a nonemployer-dominated field. Second, and larger, a channel gap: the ~$544 billion figure excludes the prescription sales embedded in Walmart, Costco, Kroger, and other non-drugstore formats, which are booked under other codes [1]. Industry trackers counting prescriptions across all channels put total U.S. dispensing revenue near $683 billion in 2024 [6], and Americans filled roughly 7.1 billion retail and long-term-care prescriptions that year [5]. So the industry that matters economically is larger and faster-growing than this drugstore-only slice — but the growth is concentrated in mail, specialty, and grocery/mass channels, not the traditional corner drugstore.

4. Investable universe (where the value sits)

With one child, the investable universe of 45611 is exactly that of 456110 — there is no cross-child allocation to make. The essential fact for investors: you cannot buy "the drugstore industry" cleanly. After a brutal three years, only one large listed pure-play chain remains (CVS Health), and even it is really an insurer-PBM-pharmacy conglomerate. The rest of the value has migrated to diversified giants where pharmacy is one segment among insurance and drug-benefit businesses (Cigna, UnitedHealth), to mass and grocery retailers (Walmart, Kroger, Costco, Albertsons), and to online entrants (Amazon). Walgreens — the #2 chain — was taken private by Sycamore Partners in 2025 [8], and Rite Aid liquidated entirely [9]. Private routes are the roughly 19,000 independent community pharmacies [10], private grocers, pharmacy real estate, and startups. Tickers, scale, and the full breakdown live in the 456110 primer.

5. How the money works

Identical to the child. A pharmacy buys a drug at an acquisition cost, then is reimbursed by a PBM or payer at a contracted rate plus a dispensing fee; gross profit per script = (reimbursement − acquisition cost) + dispensing fee. The industry's whole stress lives on that line, because the pharmacy usually does not control the final price and PBMs have driven reimbursement down for years [11]. Generics (about nine of ten U.S. prescriptions) carry high percentage margins and are the profit backbone; brand and specialty drugs move huge dollars at thin percentage spreads. The single most important economic fact is that profit has migrated out of the store into vertically integrated groups that own both a pharmacy and a PBM — which is why standalone chains have struggled to survive. Full detail (cost-plus pricing, DIR-fee reform, the metrics owners watch) is in 456110, Section 5.

6. Demand drivers

Same as the child: an aging, increasingly chronically ill population lifts prescription volume; the GLP-1 (glucagon-like peptide-1) obesity/diabetes-drug boom is a large volume tailwind but a mixed one for margin; insurance design (Medicare Part D, Medicaid, commercial coverage) sets affordability; new drug launches and list-price inflation raise dollars per script; and convenience-driven channel shift (mail, 90-day fills, home delivery) keeps moving where demand lands away from the traditional drugstore [5][6]. See 456110, Section 6.

7. Regulation

One of the most heavily regulated retail categories in America, and the rules apply identically at this level: state boards of pharmacy (licensing, staffing, ownership); the Food and Drug Administration (drug products, compounding, the Drug Supply Chain Security Act); the Drug Enforcement Administration (controlled substances); the Centers for Medicare & Medicaid Services (Part D and Medicaid reimbursement); and the Health Insurance Portability and Accountability Act (patient-data protection). The fastest-moving front is PBM and competition policy — the Federal Trade Commission has issued interim staff reports on PBM concentration, specialty markups, and spread pricing, and federal and state PBM reforms are phasing in [11]. For dispensers, tighter PBM rules are broadly a potential tailwind. Full regulatory map: 456110, Section 7.

8. Consolidation

The past three years produced the most dramatic reshaping of U.S. retail pharmacy in a generation, and it registers directly in this level's concentration figures (CR4 = 71%; HHI = 1,710.8) [2]: the "Big Three" chains became a "Big One-and-a-half" (Rite Aid liquidated [9], Walgreens went private [8], CVS is the dominant listed chain); vertical integration — pharmacy plus PBM — is the winning structure; grocery and mass merchants keep taking share; online entrants nibble from a small base; and independents are squeezed but resilient, falling to about 18,984 stores by mid-2024 while still outnumbering any single chain [10]. Access is deteriorating — nearly one in three U.S. retail pharmacies has closed since 2010, leaving roughly 50 million Americans in "pharmacy deserts" [12]. See 456110, Section 8.

9. Risks

Identical to the child, and worth stating because they explain the gap between defensive demand and stressed profit: reimbursement compression (the central risk); PBM leverage and vertical conflicts for standalone dispensers; regulatory whipsaw as PBM and Part D reforms are absorbed; fixed-cost store networks that lose operating leverage as sales shift to mail/online; labor and service pressure; drug-supply and inventory risk; GLP-1 margin dilution; data/cyber risk; and legacy liabilities (opioid settlements were fatal to Rite Aid [9]). Full discussion: 456110, Section 9.

10. How to invest and outlook

Because 45611 is a single-child pass-through, the investment picture is exactly the leaf-level one. Public exposure is mostly indirect and consolidated — CVS Health is the only large listed pure-play, and even it should be analyzed segment-by-segment (prescription volume, reimbursement per script, gross margin after PBM adjustments, payer/generic-specialty mix, store productivity, lease and debt load) rather than as a pure retail-pharmacy stock; broader exposure runs through insurer-PBMs (Cigna, UnitedHealth) and pharmacy-carrying retailers (Walmart, Kroger, Costco, Albertsons, Amazon). Private ownership usually means an independent community pharmacy (SBA small-business threshold $37.5 million in receipts [4]) or institutional stakes in private chains, real estate, private credit, and online entrants — more operating control, less disclosure and liquidity, and a thesis that rests heavily on PBM reform lifting the pay floor.

Base case: prescription volume keeps growing with demographics and new drugs, but the value of dispensing continues to concentrate in vertically integrated PBM-pharmacy platforms and lower-cost mass/grocery/online channels. The standalone corner drugstore — the archetype this NAICS code was built around — remains the part of the industry under the most durable pressure, its fate hinging more on reimbursement policy than on foot traffic.

For the complete primer — full investable universe with tickers, unit economics, the regulatory landscape, and diligence checklist — see the leaf-level page, NAICS 456110.

---

Sources

1. U.S. Census Bureau, 2022 NAICS Manual — 456110 Pharmacies and Drug Retailers (definition, cross-references, and exclusions to 524292, 456191, 424210, and store-format codes). https://www.census.gov/naics/?details=456110&input=456110&year=2022
2. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms (NAICS 45611/456110 — firms, receipts, CR4/CR8/CR20/CR50, HHI). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
3. U.S. Census Bureau, County Business Patterns, 2023 (NAICS 456110 — establishments, employment, payroll; applies to 45611 as the identical child). https://www.census.gov/data/datasets/2023/econ/cbp/2023-cbp.html
4. U.S. Small Business Administration, Table of Size Standards (2023), NAICS 456110 ($37.5M average annual receipts). https://www.sba.gov/document/support-table-size-standards
5. IQVIA Institute for Human Data Science, "The Use of Medicines in the U.S. 2024/2025" (7.1B scripts; net spend and growth; retail ~83% of use). https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2024
6. Drug Channels Institute, "The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues," March 2025 (~$683B all-channel dispensing revenue; integrated PBM-pharmacy groups). https://www.drugchannels.net/2025/03/the-top-15-us-pharmacies-of-2024-market.html
7. CVS Health Corporation, Form 10-K and 2024/2025 earnings releases (store count; segment revenue; cost-based reimbursement transition). https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2025/Q4-2024-Earnings-Release.pdf
8. Walgreens Boots Alliance / Sycamore Partners merger (announced March 2025; closed August 28, 2025; up to $23.7B). https://corporate.walgreens.com/news-and-stories/press-releases/2025/walgreen-co-to-operate-as-private-standalone-company-following-acquisition-by-sycamore-partners/
9. Fox Business, "Rite Aid files for bankruptcy for second time in less than 2 years" (2025), with subsequent full liquidation (final stores closed October 2025). https://www.foxbusiness.com/economy/rite-aid-files-bankruptcy-second-time-less-than-2-years
10. National Community Pharmacists Association, 2024 NCPA Digest (~18,984 independents June 2024; gross-margin trend). https://ncpa.org/newsroom/news-releases/2024/10/27/ncpa-releases-2024-digest-report
11. Federal Trade Commission, Interim Staff Reports on Prescription Drug Middlemen, July 2024 and January 2025 (PBM concentration, specialty markups, spread pricing). https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen
12. USC Schaeffer Center / Health Affairs, "Nearly 1 in 3 Retail Pharmacies Have Closed Since 2010," December 2024 (pharmacy deserts; ~50M affected). https://schaeffer.usc.edu/research/pharmacy-closures-united-states-health-affairs/